Literature DB >> 4024393

Preliminary results on the use of the humoral immune response as a serum marker in patients with bladder tumors.

U E Studer, J B deKernion, L Lovrekovich.   

Abstract

An immunoassay using a human bladder tumor tissue culture cell line (J-82) as antigen and a modified avidin-biotin-complex (ABC) method were used to examine human serum samples. Optical density (OD) of 26 serum samples obtained from 19 patients with bladder tumors had a mean OD of 458 +/- 71 SD (328-570). This is significantly higher (p less than 0.0005) when compared to the mean OD of 172 +/- 49 SD (107-301) found in serum samples from 28 patients with tumors other than bladder cancer and to the mean OD of 207 +/- 48 SD (136-310) of serum samples from 25 healthy donors. Thirty-one serum samples from 21 patients who had a bladder tumor surgically removed 1 to 36 months before were, with 2 exceptions, also higher than 320 (mean 412 [248-550]). All serum samples of patients with presence of a bladder tumor above the cut-off point of 320 and those from the 2 control groups below it shows, thus far, a high sensitivity as well as specificity of the method used and encourages further assessment of its potential usefulness as a serum marker assay in patients with bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4024393     DOI: 10.1007/bf00256071

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  15 in total

1.  Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma.

Authors:  T R Hakala; P H Lange; A E Castro; A Y Elliott; E E Fraley
Journal:  J Urol       Date:  1975-05       Impact factor: 7.450

2.  Loss of specific natural cell-mediated cytotoxicity with absorption of natural antibodies from serum.

Authors:  D Akira; M Takasugi
Journal:  Int J Cancer       Date:  1977-06-15       Impact factor: 7.396

3.  Demonstration of antibodies against human malignant melanoma by immunofluorescence.

Authors:  D L Morton; R A Malmgren; E C Holmes; A S Ketcham
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

4.  Proceedings: Escape from immune destruction by the host through shedding of surface antigens: is this a characteristic shared by malignant and embryonic cells?

Authors:  P Alexander
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

5.  Cellular and humoral immune responses to human urinary bladder carcinomas.

Authors:  J Bubeník; P Perlmann; K Helmstein; G Moberger
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

6.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

7.  Humoral and cellular immune reactions against tumor cells in patients with urinary bladder carcinoma. Correlation between direct and antibody-dependent cell-mediated cytotoxicity.

Authors:  Y Hansson; S Paulie; A Larsson; M L Lundblad; P Perlmann; I Näslund
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls.

Authors:  M Troye; Y Hansson; S Paulie; P Perlmann; H Blomgren; B Johansson
Journal:  Int J Cancer       Date:  1980-01-15       Impact factor: 7.396

9.  Membrane-associated antigens on tumor cells from transitional-cell carcinoma of the human urinary bladder. I. Immunological characterization by xenogeneic antisera.

Authors:  M U Schneider; M Troye; S Paulie; P Perlmann
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

10.  Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma.

Authors:  C O'Toole; Z H Price; Y Ohnuki; B Unsgaard
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more
  1 in total

1.  Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.

Authors:  A P van der Meijden; P A Steerenberg; I M van Hoogstraaten; J A Kerckhaert; L M Schreinemachers; E J Harthoorn-Lasthuizen; A M Hagenaars; W H de Jong; F M Debruijne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.